Boston, MA -- (SBWIRE) -- 10/23/2013 -- At winstonsmallcap.com we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. Let have a Look on: Allianz SE (ADR) (OTCMKTS:AZSEY), Merck & Co., Inc. (NYSE:MRK), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Generex Biotechnology Corporation (OTCMKTS:GNBT).
Allianz SE (ADR) (OTCMKTS:AZSEY) opened its shares at the price of $17.03 for the day. Its closing price was $17.24 after gaining2.44% for the day. The company traded with the total volume of 148,554 shares, while its average trading volume remained 213,319 shares. The beta of AZSEY stands at1.95.
Will AZSEY Continue To Move Higher? Find Out Here
Allianz SE primarily provides property and casualty, and life/health insurance products to private and corporate customers worldwide.
Merck & Co., Inc. (NYSE:MRK) percentage change plunged -0.09% to close at $46.47 with the total traded volume of 15.85 million shares, and average volume of 14.60 million. The 52 week range of the stock remained $40.02 - $50.16, while its day lowest price was $46.14 and it hit its day highest price at $46.72.
Will MRK Get Buyers Even After The Recent Rally? Find Out Here
Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) started its trading session with the price of $75.13 and closed at $77.62 by scoring -3.99%. VRTX’s stocks traded with total volume of 1.53 million shares, while the average trading volume remained 3.20 million shares. The beta of VRTX stands at 0.56. Day range of the stock was $74.94 -$77.98.
Will VRTX Continue To Move Higher? Find Out Here
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases.
Generex Biotechnology Corporation (OTCMKTS:GNBT) ended its day with the gain of 2.26% and closed at the price of $0.317 after opening at $0.03. Stock traded during its last trading session with the total volume of 1.65 million shares, as compared to its average volume of 1.92 million shares.
Will GNBT Continue To Move Higher? Find Out Here
Generex Biotechnology Corporation, a development stage company, is engaged in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases.
Here at Winston we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. We focus on companies that we feel are trading at a discount to the market for various reasons. Enter your email and track our performance! We are sure you won’t be disappointed.
http://winstonsmallcap.com/ and its owners, and their affiliates, directors and officers, and immediate family members, are hereafter collectively referred to as “WSC” or “we” or “us” or “our”). WSC publishes information (the “Information”) about publicly traded companies (the “Profiled Company” or the “Profiled Companies”) which has been obtained from various sources including publicly available sources on the internet. WSC does not undertake any due diligence or investigation of the Information it obtains or publishes.
Read Full Disclaimer at: http://winstonsmallcap.com/disclaimer
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)